Cumberland Pharmaceuticals (CPIX) EBIT Margin (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted EBIT Margin of 34.27% for Q1 2026, down 241.86% sequentially from 10.02% in Q4 2025, and down 4530.0% YoY from 0.77% in Q1 2025.
Cumberland Pharmaceuticals (CPIX) EBIT Margin (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported EBIT Margin for 17 years, with the latest figure at 34.27% in Q1 2026.
- Quarterly EBIT Margin fell 4530.0% year-over-year to 34.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.2% (down 924.0% YoY) and the FY2025 annual result came in at 6.27%, up 1072.0% from the prior year.
- EBIT Margin declined to 34.27% in Q1 2026 per CPIX's latest filing, from 10.02% in the prior quarter.
- Over five years, EBIT Margin peaked at 11.03% in Q1 2025 and troughed at 66.07% in Q4 2023.
- A 5-year average of 17.09% and a median of 17.65% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2024 and 2026: EBIT Margin soared 4841 bps in 2024, then tumbled 4530 bps in 2026.
- Over 5 years, EBIT Margin stood at 24.97% in 2022, then tumbled by 165 bps to 66.07% in 2023, then soared by 73 bps to 17.65% in 2024, then soared by 43 bps to 10.02% in 2025, then plunged by 242 bps to 34.27% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 34.27%, 10.02%, and 23.7% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Cumberland Pharmaceuticals | 117.68 Mn | 113.82 Mn | - | -1,898.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,898.65% |
| Mar 31, 2026 | -34.27% |
| Dec 31, 2025 | -10.02% |
| Sep 30, 2025 | -23.70% |
| Jun 30, 2025 | -6.90% |
| Mar 31, 2025 | 11.03% |
| Dec 31, 2024 | -17.65% |
| Sep 30, 2024 | -18.65% |
| Jun 30, 2024 | -10.42% |
| Mar 31, 2024 | -22.00% |
| Dec 31, 2023 | -66.07% |
| Sep 30, 2023 | -18.51% |
| Jun 30, 2023 | 0.21% |
| Mar 31, 2023 | -16.60% |
| Dec 31, 2022 | -24.97% |
| Sep 30, 2022 | -2.53% |
| Jun 30, 2022 | -17.93% |
| Mar 31, 2022 | -11.56% |
| Dec 31, 2021 | -52.33% |
| Sep 30, 2021 | -19.37% |